Cambrex Co. (CBM) Holdings Raised by Boston Partners

Boston Partners boosted its holdings in shares of Cambrex Co. (NYSE:CBM) by 118.5% in the 4th quarter, Holdings Channel reports. The fund owned 709,786 shares of the biotechnology company’s stock after buying an additional 384,897 shares during the quarter. Boston Partners’ holdings in Cambrex were worth $34,069,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of CBM. Amalgamated Bank increased its stake in Cambrex by 6.1% during the second quarter. Amalgamated Bank now owns 4,473 shares of the biotechnology company’s stock worth $267,000 after acquiring an additional 258 shares during the last quarter. Northern Trust Corp boosted its position in shares of Cambrex by 3.7% during the second quarter. Northern Trust Corp now owns 566,302 shares of the biotechnology company’s stock worth $33,837,000 after buying an additional 19,955 shares during the period. FMR LLC boosted its position in shares of Cambrex by 19.1% during the second quarter. FMR LLC now owns 1,070,645 shares of the biotechnology company’s stock worth $63,971,000 after buying an additional 171,559 shares during the period. California Public Employees Retirement System boosted its position in shares of Cambrex by 4.4% during the second quarter. California Public Employees Retirement System now owns 73,500 shares of the biotechnology company’s stock worth $4,392,000 after buying an additional 3,100 shares during the period. Finally, Suntrust Banks Inc. boosted its position in shares of Cambrex by 2.8% during the second quarter. Suntrust Banks Inc. now owns 7,355 shares of the biotechnology company’s stock worth $439,000 after buying an additional 201 shares during the period.

CBM has been the subject of several research analyst reports. Zacks Investment Research upgraded Cambrex from a “strong sell” rating to a “hold” rating in a research report on Monday, January 15th. Craig Hallum restated a “buy” rating and set a $60.00 price target (down from $70.00) on shares of Cambrex in a research report on Tuesday, October 31st. Finally, William Blair initiated coverage on Cambrex in a research report on Tuesday, January 16th. They set an “outperform” rating for the company. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. Cambrex has an average rating of “Hold” and an average target price of $60.00.

Cambrex Co. (CBM) opened at $53.00 on Thursday. Cambrex Co. has a 52-week low of $42.55 and a 52-week high of $62.95. The company has a market capitalization of $1,740.00, a price-to-earnings ratio of 17.41, a PEG ratio of 1.24 and a beta of 2.38.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at https://www.com-unik.info/2018/02/08/cambrex-co-cbm-holdings-raised-by-boston-partners.html.

Cambrex Profile

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).

Institutional Ownership by Quarter for Cambrex (NYSE:CBM)

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit